Evidence map›Paper›PMID 39666205›Full record

ArticleJournal of molecular modeling2024

Docking heparan sulfate-based ligands as a promising inhibitor for SARS-CoV-2.

Luiz F M A Benício, Érica C M Nascimento, João B L Martins

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of molecular modeling, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Luiz F M A BenícioDepartment of Pharmacy, Faculty of Health Sciences, University of Brasília, Brasília, DF, 70910-900, Brazil.
Érica C M NascimentoComputational Chemistry Laboratory, Institute of Chemistry, University of Brasilia, Brasilia, DF, 70910-900, Brazil.ORCID http://orcid.org/0000-0003-1365-177X
João B L MartinsDepartment of Pharmacy, Faculty of Health Sciences, University of Brasília, Brasília, DF, 70910-900, Brazil. lopes@unb.br.ORCID http://orcid.org/0000-0001-8677-3239

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico 306682/2021-4Fundação de Apoio à Pesquisa do Distrito Federal 00193-00000869/2021-31
6 · The paper itself

Abstract

contextHeparan sulfate (HS) linear polysaccharide glycosaminoglycan compound is linked to components from the cell surface and the extracellular matrix. HS mediates SARS-CoV-2 infection through spike protein binding to cell surface receptors and is required to bind ACE2, prompting the need for electronic structure and molecular docking evaluation of this core system to exploit this attachment in developing new derivatives. Therefore, we have studied five molecules based on HS using molecular docking and electronic structure analysis. Non-covalent interaction analysis shows hydrogen bonding and van der Waals interactions in the binding to RBD-ACE2 interface and 3CL

methodsHeparan sulfate and four derivatives were optimized using B3LYP functional with two basis sets 6-31 + G(d,p) and def2SVP. Electronic structure was used to explore the main interactions and the reactivity of these molecules, and these optimized structures were used in the molecular docking study against 3CL

Indexed as

Angiotensin-Converting Enzyme 2Antiviral AgentsHeparan SulfateMolecular Docking SimulationSARS-CoV-2Binding SitesCoronavirus 3C ProteasesCOVID-19COVID-19 Drug TreatmentHumansHydrogen BondingLigandsProtein BindingSpike Glycoprotein, CoronavirusACE2 protein, humanAngiotensin-Converting Enzyme 2Antiviral AgentsCoronavirus 3C ProteasesHeparan SulfateLigandsSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2B3LYPHeparan sulfateMolecular dockingSARS-CoV-2

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.